Interfacial Phase Behavior of Pulmonary Surfactant

肺表面活性剂的界面相行为

• 批准号: 6779061
• 负责人: STEPHEN B HALL
• 金额: $ 36.74万
• 依托单位: OREGON HEALTH & SCIENCE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-08-01 至 2006-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6779061
• 关键词: cholesterol; compression; fluorescence microscopy; laboratory rat; lung alveolus; mechanical pressure; palmitates; phosphatidylcholines; phospholipids; pulmonary surfactants; respiratory epithelium; respiratory function

DESCRIPTION (provided by applicant): This proposal concerns the mechanisms by which thin films of pulmonary surfactant form solid structures in the lungs. Surfactant films stabilize the small air spaces of the lungs by lowering the surface tension of the thin liquid layer that lines the alveoli. When compressed by the decreasing surface area during exhalation, the surfactant film reduces surface tension to extraordinarily low levels. In vitro, compressed monolayers containing the complete set of surfactant constituents fail to reach such low surface tensions because above an equilibrium density, constituents collapse from the interface. The ability of the two dimensional films to flow into the third dimension indicates fluid behavior. In the lungs, the persistence of the surfactant films at the interface when compressed to densities well above equilibrium indicates a solid structure. The classical model of surfactant function contends that only a film in the highly ordered tilted-condensed (TC) phase can be compressed to the low surface tensions observed in the lungs. Of the components in lung surfactant, only its most prevalent constituent, dipalmitoyl phosphatidylcholine (DPPC), can form the TC phase at physiological temperatures. Therefore the classical model explains the transformation of the surfactant film from fluid to solid structures in terms of a change in composition, with elimination of constituents other than DPPC, and a consequent transition between equilibrium phases. Our recently published and preliminary unpublished data, however, disagree with the predictions of the classical model. Our results suggest instead that the fluid surfactant films transform to solid structures by a process analogous to the supercooling of three dimensional liquids to form glass. The experiments proposed here will test first if fluid films transformed to solid structures by supercompression in vitro replicate the behavior of pulmonary surfactant in physiological settings, and then the extent to which the supercompressed fluid monolayers fit predictions of the analogy with supercooled liquids.

描述(申请人提供)：本提案涉及肺表面活性物质薄膜在肺内形成固体结构的机制。表面活性物质膜通过降低肺泡内薄液层的表面张力来稳定肺部的小空气空间。当在呼气过程中被减小的表面积压缩时，表面活性剂膜将表面张力降低到非常低的水平。在体外，含有一整套表面活性剂成分的压缩单分子膜无法达到如此低的表面张力，因为在平衡密度以上，成分从界面坍塌。二维薄膜流入三维空间的能力表明了流体的行为。在肺中，当压缩到远高于平衡的密度时，表面活性物膜在界面上的持久性表明了一种固体结构。经典的表面活性物质功能模型认为，只有高度有序的倾斜-凝聚(TC)相的膜才能压缩到在肺中观察到的低表面张力。在肺表面活性物质的成分中，只有其最常见的成分二棕榈酰磷脂酰胆碱(DPPC)在生理温度下能形成TC相。因此，经典模型从组成的变化解释了表面活性剂膜从流体到固体结构的转变，消除了DPPC以外的其他成分，并由此导致了平衡相之间的转变。然而，我们最近发表的和初步未发表的数据与经典模型的预测不一致。相反，我们的结果表明，流体表面活性剂薄膜通过类似于三维液体过冷形成玻璃的过程转变为固体结构。这里提出的实验将首先测试在体外通过超压缩转变为固体结构的流体膜是否复制了生理环境中肺表面活性物质的行为，然后测试超压缩流体单分子层与过冷液体的相似预测的程度。